Summary
Cencora, Inc. (formerly AmerisourceBergen Corporation) filed an 8-K on October 18, 2020, reporting material definitive agreements related to its securitization facility. The key event was the entry into several amendments to its receivables sale and purchase agreements, significantly enhancing its liquidity and funding capabilities. These amendments include adding ASD Specialty Healthcare, LLC as a new originator, expanding the pool of receivables available for securitization, and ensuring the facility's adaptability to future financial market changes, such as the transition away from LIBOR. This filing is important for investors as it demonstrates the company's proactive approach to managing its financial resources and ensuring ongoing business needs are met. The expansion of the securitization facility, with a base limit of $1,450 million and an option to increase by $250 million, provides substantial flexibility. The inclusion of ASD as an originator diversifies the receivable sources and potentially increases borrowing capacity. The company's role as a performance guarantor underscores its commitment to the facility's stability and its own financial health.
Key Highlights
- 1Cencora, Inc. (COR) entered into material definitive agreements on October 16, 2020, related to its securitization facility.
- 2ASD Specialty Healthcare, LLC was added as a new originator to the securitization facility.
- 3The amendments provide for the transition to a new interest rate benchmark when LIBOR is no longer available.
- 4The securitization facility is designed to provide additional liquidity and funding for ongoing business needs.
- 5The facility's borrowing base is comprised of accounts receivables from the sale of pharmaceuticals and related services.
- 6The securitization facility has a base limit of $1,450 million, with an option to increase by $250 million for seasonal needs.
- 7Cencora, Inc. acts as the performance guarantor for the obligations under the securitization facility.